Using univariate Cox regression analysis, we further confirmed that KRAS G12/G13 mutation status in cfDNA is a prognostic indicator of unfavorable PFS and OS in NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.